ATARAXIS — switch on the algorithm of precision in the fight against breast cancer
Warsaw Genomics is the official distributor of Ataraxis tests in Poland. We handle test ordering, transport, material scanning and result delivery.
The first fully AI-based diagnostic system
ATARAXIS is the first clinically validated diagnostic system based entirely on artificial intelligence (AI), for patients with invasive breast cancer at stages I–III.
Ataraxis Breast integrates analysis of histopathology slide images with clinical data, giving the physician objective information that helps choose the right systemic treatment.
Key test parameters
Fast analysis and result
The analysis is performed digitally and the result is available within a few business days — so a treatment decision can be made quickly, without waiting weeks for genomic tests.
High precision
In a study of over 10,000 patients, the AI system achieved ~50% higher accuracy in predicting breast cancer recurrence compared with genomic tests.
Material preservation
The analysis is based on a single, already existing slide from a biopsy or surgery — no additional sampling required.
Comprehensiveness
Helps personalise the choice of therapy by assessing recurrence risk, the benefit of adjuvant chemotherapy (in HR+/HER2− patients) and response to neoadjuvant treatment.
Diagnostic parameters per the manufacturer of the Ataraxis Breast system. ATARAXIS supports — and does not replace — the physician's clinical decision.
Ataraxis™ Breast is a tool that supports the oncologist in deciding to de-escalate treatment (avoiding unnecessary chemotherapy) or to intensify it in a targeted way — giving patients therapeutic safety based on hard medical data.
Order the test HERE.
When ordering the test, use the code: ATARAXIS and join the free pilot programme.
Want to order the ATARAXIS test?
Contact us — we will guide you through ordering, sample transport and result delivery.